News / Press Releases - September 6, 2023
6 September 2023, Brussels – EUCOPE, as part of a multi-stakeholder group consisting of 32 European patient organisations, medical associations, research organisations, data collaborations and industry associations met EU officials, including MEP Tomislav Sokol, Co-Rapporteur, as well as several permanent representations that will hold upcoming… read more
News - August 18, 2023
EUCOPE’s Sounds of Science Podcast – Episode 17 Real-World Evidence (RWE): The need for a multi-stakeholder approach Within the EU, the life sciences industry requires a strong innovation framework across the patient journey so that such technological advancements can be used to the benefit of… read more
News - July 21, 2023
On 18 July, European lawmakers within the Health and Environment (ENVI) committee voted to adopt the amended report on Substances of Human Origin (SoHo). The report aims to improve the safety and quality standards for both donors and recipients of blood, plasma, skin, embryo, sperm,… read more
EUCOPE Resources / News - July 14, 2023
On 7 July, EUCOPE – the European Confederation of Pharmaceutical Entrepreneurs – hosted the second episode of its Life Science Lectures webinar series. The focus of the webinar, titled ‘’Defining (high) unmet medical need: will it steer innovation towards filling existing gaps?’’, was to dive… read more
EUCOPE Resources / News / Press Releases - July 13, 2023
On 12 July 2023, EUCOPE’s HERA Steering Group released its White Paper “EU-wide Stockpiling: Better Preparedness for Cross-Border Health Threats.” Stockpiling of critical biomedical countermeasures is crucial for an effective EU preparedness against priority cross-border health threats with a potentially large health and societal impact…. read more
EUCOPE Resources / News - July 12, 2023
EUCOPE’S Sounds of Science Podcast – Episode 16 Rare Reflections: Impact of the OMP revision on rare disease companies in Europe On 26 April 2023, the European Commission published its long awaited proposal revising the foundational pharmaceutical legislation, including the Orphan Medicinal Products (OMP) Regulation…. read more
Member Spotlight / News / Press Releases - June 29, 2023
The European Confederation of Pharmaceuticals Entrepreneurs (EUCOPE) announced the joining of six (6) new members at its quarterly Members Meeting on June 21st, 2023 following Board approval. The new members joining EUCOPE network are Azafaros, Deciphera Pharmaceuticals, Dyne Therapeutics, HemaNext, MediWound and Rocket Pharmaceuticals. During… read more
News / Partnerships / Press Releases - June 19, 2023
EUCOPE, along with Exact Sciences, Guardant Health, Illumina, MSD and Novartis, launch the European Coalition for Access to Comprehensive Genomic Profiling (ECGP) The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) along with Exact Sciences, Guardant Health, Illumina, MSD and Novartis, launch the European Coalition for Access… read more
EUCOPE Resources / News - June 9, 2023
On 30 May, EUCOPE – the European Confederation of Pharmaceutical Entrepreneurs hosted the inaugural episode of its Life Science Lectures webinar series, “Attaching conditionalities to incentives: the right path to improve access?” The episode delved into the incentive system outlined in the EU Pharmaceutical Package,… read more
News / Press Releases - June 9, 2023
In October 2022, EUCOPE joined a large group of European stakeholders to welcome the European Commission’s proposal on the European Health Data Space (EHDS), and to highlight common recommendations. We share the view that health data are precious and renewable resources that can power decision-making… read more
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information